Spirulina and DVT/PE: hypercoagulability, anticoagulant interactions, and iron in post-thrombotic syndrome

VTE pathophysiology and spirulina mechanisms

Endothelial component (Virchow’s triad — vessel wall): Endothelial injury and dysfunction drive VTE initiation. Endothelial NOX2 activation reduces NO bioavailability, increases tissue factor expression, and activates NF-κB — shifting the endothelial surface toward a pro-coagulant state. Phycocyanobilin’s endothelial NOX2 inhibition preserves NO and may reduce endothelial tissue factor expression. This is a modest effect and does not constitute anticoagulant activity.
Platelet component: Spirulina has mild antiplatelet activity (inhibits platelet aggregation in vitro). This is a haemostatic concern in the context of anticoagulant therapy, not a VTE prevention mechanism.
What spirulina does not do: It does not inhibit coagulation factors (like warfarin or DOACs), does not inhibit thrombin directly, does not reduce fibrin formation, and should never be presented or self-used as a VTE prevention or treatment strategy.

This is the most important interaction in VTE management. Spirulina contains vitamin K (primarily phylloquinone, ~20–30 µg/10 g). While this is a small amount relative to dietary greens (kale contains ~700 µg/100 g), consistency is critical on warfarin — any variation in dietary vitamin K intake shifts the INR.
Rule: Take the exact same spirulina dose every day if on warfarin. Do not take spirulina some days and not others. Start at a low consistent dose (2–3 g/day). Check INR 2 weeks after starting spirulina to determine if dose adjustment is needed. The warfarin dose should adjust to your consistent spirulina intake — not the other way around.
Do not use green spirulina shots or smoothies with variable spirulina content alongside warfarin — dose variability will cause INR variability. Use weighed, consistent powder doses.

DOACs are the preferred anticoagulants for most VTE. They do not interact with vitamin K; INR is not relevant. No pharmacokinetic interaction between spirulina and DOACs.
Mild spirulina antiplatelet activity adds to the bleeding risk of any anticoagulant. At standard 3–5 g/day spirulina with therapeutic DOAC: no significant clinical bleeding risk increase is anticipated, but inform your haematology or anticoagulation clinic. Higher doses (>8 g/day): not recommended without discussion.

LMWH (enoxaparin, tinzaparin) is used in acute VTE treatment, pregnancy, and cancer-associated thrombosis. No pharmacokinetic interaction with spirulina. The mild antiplatelet addition from spirulina is not expected to be clinically significant alongside therapeutic LMWH in most patients.

Post-thrombotic syndrome (PTS) affects 20–50% of DVT patients — chronic venous hypertension, leg oedema, pigmentation, and ulceration from valve damage and persistent venous inflammation. Venous wall inflammatory infiltrate in PTS involves activated macrophages and neutrophils with NOX2 activity; phycocyanobilin’s NOX2 inhibition may reduce ongoing venous wall damage in PTS.
Iron is commonly low in post-thrombotic patients with concurrent inflammation (ACD pattern). Ferritin may be elevated by acute-phase reactants. Use transferrin saturation to assess true iron status in PTS with inflammatory markers.

Antiphospholipid syndrome (APS): APS requires indefinite anticoagulation (warfarin target INR 2–3, or 3–4 in high-risk). The warfarin vitamin K consistency rule applies fully. Discuss with haematologist. Spirulina NK stimulation is relevant in APS with autoimmune comorbidity (lupus-APS overlap): discuss with rheumatologist.
Factor V Leiden, prothrombin mutation: Inherited thrombophilias without ongoing anticoagulation: no specific spirulina concern. Standard 3–5 g/day with adequate hydration.
Cancer-associated thrombosis on LMWH or DOAC: Inform oncology team. Cancer treatment context (chemotherapy) may complicate any supplement assessment.

On warfarin: weighed consistent daily dose (2–5 g/day); never vary dose day to day; INR check 2 weeks after starting; inform anticoagulation service
On DOAC: 3–5 g/day; no vitamin K concern; inform anticoagulation clinic of mild antiplatelet addition at higher doses
Spirulina is NOT an anticoagulant, NOT a VTE prophylaxis, and should never substitute for prescribed anticoagulation
Post-thrombotic syndrome: 3–5 g/day; check iron status with transferrin saturation; phycocyanobilin venous wall anti-inflammatory effect is speculative but mechanistically sound